Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population

Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population–Based Analysis

Published:2020-01 Issue:1 Volume:115 Page:128-137
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:Am J Gastroenterol

Author:

Targownik Laura E.,Kaplan Gilaad G.,Witt Julia,Bernstein Charles N.,Singh Harminder,Tennakoon Aruni,Aviña Zubieta Antonio,Coward Stephanie B.,Jones Jennifer,Kuenzig M. Ellen,Murthy Sanjay K.,Nguyen Geoffrey C.,Peña-Sánchez Juan Nicolás,Benchimol Eric I

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group;Targan;N Engl J Med,1997

2. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial;Hanauer;Lancet,2002

3. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

4. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

5. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis;Panaccione;Gastroenterology,2014

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microbial assimilatory sulfate reduction-mediated H2S: an overlooked role in Crohn’s disease development;Microbiome;2024-08-16

2. The Cost of Inflammatory Bowel Disease Care – How to Make it Sustainable;Clinical Gastroenterology and Hepatology;2024-08

3. High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data;Inflammatory Bowel Diseases;2024-07-19

4. Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis—results from the IBSEN III inception cohort;Alimentary Pharmacology & Therapeutics;2024-06-04

5. Clinical and health care utilization variables can predict 90-day hospital re-admission in adults with Crohn’s disease for point of care risk evaluation;BMC Gastroenterology;2024-05-17